Management at Varian Medical Systems Oncology Systems business unit has been restructured to consolidate global operations and provide additional management resources for developing early-stage emerging businesses, according to company CEO and president
Management at Varian Medical Systems Oncology Systems business unit has been restructured to consolidate global operations and provide additional management resources for developing early-stage emerging businesses, according to company CEO and president Richard M. Levy. Tim Guertin is the company's new executive vice president. Guertin will continue as president of Varian's Oncology Systems business in addition to assisting Levy with corporate issues. Several other new appointments were made within Oncology Systems.
John Ford, corporate vice president, has been named senior vice president for Oncology Systems, responsible for facilitating major customer, government, and partnering initiatives. Jeff Marcus, vice president of Oncology Systems, will assume responsibility for the worldwide sales organization. Paul Rowland, vice president of North American sales, Oncology Systems, will head the sales organization in the U.S. and Canada. He will report to Marcus. The medical manufacturing operations for Oncology Systems will be combined under Keith Krugman, corporate vice president and vice president, Oncology Systems, who will have continuing responsibility for worldwide customer support functions. Elaine McKinley has been appointed vice president, Oncology Systems customer support, reporting to Krugman. Product engineering and marketing have been combined under the direction of Kolleen Kennedy, vice president, Oncology Systems. Ueli Graf, vice president, worldwide engineering, Oncology Systems, will report to Kennedy.
Assessing MACE Risk in Women: Can an Emerging Model with SPECT MPI Imaging Have an Impact?
December 9th 2024In research involving over 2,200 women who had SPECT MPI exams, researchers found that those who had a high score with the COronary Risk Score in WOmen (CORSWO) model had a greater than fourfold higher risk of major adverse coronary events (MACE).